IGlar, respectively. Odds ratios for achieving HbA 1c \7.0%,\7.0% without hypoglycemia, and \7.0% without hypoglycemia and no weight gain were greater with IDegLira versus up-titrated IGlar. The supplementary analysis yielded similar results to the main analysis.
Results: At end of study, differences between IDegLira and BB or up-titrated IGlar, respectively, were as follows: reduction in HbA 1c -0.30%, 95% confidence interval (-0.58; -0.01) and -0.65% (-0.83; -0.47); change in body weight -6.89 kg Electronic supplementary material The online version of this article (doi:10.1007/s13300-015-0142-y) contains supplementary material, which is available to authorized users. (-7.92 
INTRODUCTION
When patients with type 2 diabetes do not achieve glycemic control with basal insulin, common strategies are to titrate the basal insulin further, add bolus insulin, or switch to premix insulin. These options improve glycemic control but may increase rates of hypoglycemia and weight gain. A more recent option has been to add a glucagon-like peptide-1 receptor agonist (GLP-1RA) to the basal insulin [1, 2] , which has potential advantages. With their different modes of action, basal insulin and GLP-1RAs target several of the multiple pathophysiological defects that contribute to type 2 diabetes.
By supplementing endogenous insulin secretion, basal insulin may also facilitate beta-cell rest and hence restore the prandial insulin response to some degree [3, 4] .
GLP-1RAs stimulate insulin secretion and suppress glucagon secretion in a glucose-dependent manner [5, 6] , as well as delaying gastric emptying and reducing appetite [7] . Gastrointestinal adverse events (AEs), in particular nausea, are associated with GLP-1RAs [8] . GLP-1 itself increases satiety [9] ;
the GLP-1RA liraglutide has been shown to exert the same effect [10] , and to be associated with weight loss [8] .
Combining a basal insulin and a GLP-1RA has the potential to yield improved clinical results to those expected from either therapy alone-providing better glycemic control arising from reductions in both fasting plasma glucose (FPG) and postprandial glucose, and less associated hypoglycemia and less weight gain compared with the use of basal insulin alone [11] . This has indeed been the case; for example, in the VICTOZA ADD-ON study (NCT01388361), addition of the GLP-1RA liraglutide to insulin degludec resulted in greater reductions in glycated hemoglobin (HbA 1c ) at 26 weeks relative to adding a single daily dose of insulin aspart [12] . Weight loss and lower rates of hypoglycemia were observed in the liraglutide plus insulin degludec group.
Insulin degludec/liraglutide (IDegLira) is a novel, once-daily combination of insulin degludec and liraglutide in one pen device. Insulin degludec is a once-daily basal insulin with an ultra-long duration of action. [13, 14] ; and DUAL II (NCT01392573; IDegLira versus capped-dose insulin degludec in patients uncontrolled on basal insulin plus OADs) [15] . In DUAL I, IDegLira was superior to liraglutide alone, and non-inferior to insulin degludec, in reducing mean HbA 1c from baseline. Confirmed hypoglycemia occurred less frequently with IDegLira than with insulin degludec, but significantly more frequently than with liraglutide. Patients using IDegLira lost weight, with lower weight loss versus liraglutide, while patients treated with insulin degludec gained weight [13] .
DUAL II enrolled patients who had not achieved control on basal insulin therapy [15] .
In DUAL II, mean HbA 1c reduction from baseline was greater with IDegLira versus capped-dose insulin degludec; the risk of hypoglycemia was low and comparable to that with insulin degludec; and patients lost weight with IDegLira but not with insulin degludec [15] . However, the insulin treatment arm had the dose capped at 50 units, to meet regulatory requirements and illustrate the potential [16] , and has been used previously for indirect comparisons in diabetes [17] .
METHODS

Choice of Analysis and Source of Data
To evaluate the efficacy of IDegLira compared with commonly used basal insulin intensification strategies in a population inadequately controlled on basal insulin, a pooled multivariable analysis using treatment arms from different trials was applied. For these analyses, we used individual patient-level data available in the Novo Nordisk clinical trial database, from trials that met specific criteria. Trials were identified by conducting a search using the 'TrialTrove' database of clinical trials intelligence (search strategy is shown in Figure S1 ). Briefly, to qualify, trials had to be phase III or IV randomized controlled trials (RCTs) that used IDegLira, insulin glargine (IGlar), insulin detemir, or liraglutide as the intervention drug. To eliminate bias in the selection of patients, extension studies, or studies that re-randomized patients from an immediate preceding trial, did not qualify.
Studies had to have been conducted in the target population, i.e., patients with type 2 diabetes already using a basal insulin but with uncontrolled glycemia. Studies also had to include a treatment arm that used either IDegLira or a current standard of care for such patients (see Figure S1 for details). These criteria were applied to ensure similar patient populations and similar trial designs. Five trials (including DUAL II) that met all these criteria were identified (Table 1 ) [15, [18] [19] [20] [21] . In all the trials, insulin was titrated to FPG targets similar to those used in DUAL II [72-90 mg/dL (4.0-5.0 mmol/L)]. However, in the LIRA-ADD2BASAL study (NCT01617434) [18] , the pre-trial insulin dose was reduced by 20% when patients entered the trial; this mimics clinical practice, where the initiation of liraglutide as add-on to basal insulin is accompanied by a reduction in insulin dose.
Following randomization, insulin adjustments above pre-trial dose were not allowed, as the objective was to assess the effect of the added liraglutide. Trials of non-injectable add-on therapies to basal insulin (such as pioglitazone, gliptins or sodium-glucose co-transporter-2 inhibitors)
were not included in this analysis because the Novo Nordisk clinical trial database did not include any such trials that fulfilled the selection criteria at the time of the analysis, and therefore individual patient-level data were not available.
All of the identified trials were controlled, randomized, parallel-group trials, and were either open-label or double-blind. In general, only one treatment arm, or a subset of one treatment arm, from each trial was used, as the objective was to compare the efficacy of IDegLira in DUAL II to other treatment regimens. For basal-bolus therapy, initially only patients treated with IGlar ? insulin aspart were included in the pooled analysis, but a supplementary analysis was also performed that included patients treated with insulin degludec ? insulin aspart as well (see below). Neutral protamine Hagedorn was not included as a comparator because it was not used in any of the identified trials.
The use of treatment arms from different trials raised the potential for systematic differences in the patient populations. To account for differences between the cohorts, additional baseline characteristics as compared to the models used in the original trials (listed below under ''Statistical Methods'') were included in the pooled statistical analyses.
This was possible because the analyses were based on individual patient-level data.
Outcome Measures
The primary endpoint was change in HbA 1c from baseline to end of study. Secondary endpoints were confirmed hypoglycemia (with rates reported for overall, severe, and non-severe episodes); change from baseline in body weight and body mass index (BMI); and 
Statistical Methods
When analyzing the results from a randomized controlled trial, randomization accounts for systematic bias, but subjects' baseline values may be accounted for using multivariable statistical methods to estimate the endpoint conditional on the pretreatment value, and consequently increase statistical efficiency. In the current analysis, the conventional statistical models that were pre-specified for analysis of data from the DUAL II trial were supplemented by including a number of additional clinically relevant baseline characteristics in an attempt to account for systematic differences between patients, as comparisons did not have the protection from bias achieved through randomization.
The explanatory variables used in the pooled statistical analyses were region, previous antidiabetic treatment, and baseline value of the variable being analyzed (e.g., baseline value of HbA 1c for the analysis of change in HbA 1c ).
Baseline value was not included for the analyses of dose because all patients were titrated towards a similar FPG target; thus, baseline dose would not have an impact on any of the end-of-trial treatment effects. In addition, the following variables were included to account for potential systematic differences between trial populations: sex, disease duration, baseline HbA 1c , and baseline BMI. The baseline HbA 1c and baseline BMI were included as explanatory variables in analyses of all the endpoints, not just analyses of HbA 1c and BMI, respectively. These additional explanatory variables were identified on the basis that they are clinically relevant variables, which have the potential to exert an impact on the clinical outcomes of interest in the pooled analysis.
Weight Compared with GLP-1RA add-on, IDegLira required a similar dose of basal insulin, but a lower dose of GLP-1 RA (Table 3a) .
The supplementary analysis (Table S2a and   b) , with an increased number of subjects in the BB arm, yielded very similar results to the main analysis.
As expected, estimated changes from baseline were slightly different from the observed changes (Table S3) 
Hypoglycemia
Estimated rates of hypoglycemia are shown in Table 4a and observed rates in Table S3 ; rate ratios (IDegLira relative to alternative regimen) and P values are shown in Table 4b . Estimated rates of overall hypoglycemia and non-severe hypoglycemia were significantly lower with IDegLira with BB or up-titrated basal insulin therapy (P\0.0001) ( yielded similar results to the main analysis.
Responder Rates
Estimated responder rates and odds ratios (ORs) for these rates, for IDegLira versus comparators, In the supplementary analyses, estimated ORs in all three response categories were significantly greater with IDegLira versus up-titrated IGlar, similar to the main analysis.
In addition, with the use of a larger BB group, estimated ORs in all three response categories were significantly greater with IDegLira versus BB ( Table S5a, glucose after all meals in addition to its effect in reducing FPG [24] . Improved glycemic control is achieved with lower constituent doses of liraglutide and insulin degludec than would be required for equivalent benefits using one or the other treatment independently, as was seen in the DUAL I trial [13] .
Two effects may have contributed to the reduction in body weight seen with IDegLira and with GLP-1RA add-on to basal insulin. First, treatment with liraglutide results in weight loss [25] . Second, basal insulin is normally associated with weight gain, and this was indeed seen in the BB and basal-only treatment arms, where insulin could be fully titrated and end-of-trial doses of insulin were higher than in the two treatment arms that combined basal insulin with liraglutide.
Changes in markers of cardiovascular risk other than weight/BMI were included in these analyses because previous studies have reported improved SBP [25, 26] and blood lipid profiles with liraglutide [27, 28] , and it was anticipated that a therapy including liraglutide may provide superior results versus therapies that do not.
Results were generally improved with IDegLira versus BB or up-titrated basal insulin therapy for SBP, total cholesterol, and LDL cholesterol. For these outcomes, results in the GLP-1RA add-on to basal insulin group were similar to those seen with IDegLira. Patterns of change in HDL and triglycerides did not differ systematically between treatment arms.
Rates of hypoglycemia were significantly lower with IDegLira versus BB or up-titrated basal insulin therapy, despite a mean reduction in HbA 1c that was significantly greater with IDegLira. This result was expected because the liraglutide component of IDegLira stimulates insulin secretion and suppresses glucagon secretion in a glucose-dependent manner [5, 24] . Furthermore, the use of a GLP-1RA results in a lower dose of insulin being required, as was seen in these analyses, which may further decrease the risk of hypoglycemia. Results for IDegLira and the GLP-1RA add-on to basal insulin arm were, as expected, similar except for reduction in HbA 1c . For some parameters (change in body weight, BMI, total cholesterol, LDL), numerically greater improvements were seen in the GLP-1RA add-on to basal insulin arm than with IDegLira. These differences might be explained by the fact that individual titration of IDegLira resulted in lower doses of liraglutide compared to the GLP-1RA add-on to basal insulin arm, and also the design of the GLP-1RA add-on trial, in which insulin adjustments above pre-trial dose were not allowed post-randomization, since the objective was to assess the effect of the added liraglutide [18] .
A potential advantage of IDegLira versus GLP-1RA add-on to basal insulin, not assessed here, is the greater convenience that a single once-daily injection offers patients. Also, the slower titration of liraglutide in the IDegLira arm, which follows the titration schedule for the basal insulin component, is expected to give rise to less nausea compared with independent titration of liraglutide [13] .
Responder rates for patients achieving a target HbA 1c of 7.0% (53 mmol/mol), and composite response rates that included achievement of HbA 1c target together with no hypoglycemia or no hypoglycemia and no weight gain, were greater with IDegLira versus up-titrated basal insulin therapy and versus BB therapy. Side effects of therapy such as hypoglycemia and weight gain may be of substantial concern to patients and can be barriers to achieving good HbA 1c control from both patients' and physicians' perspectives [29] [30] [31] [32] Safety was not specifically considered in this analysis, apart from hypoglycemia. In the trials used for the analysis [18] [19] [20] [21] , AEs typical of basal insulin and/or GLP-1RA therapy were noted, with no major or unexpected patterns or concerns arising. In DUAL II, the incidence of gastrointestinal AEs was low, but slightly higher for IDegLira versus insulin degludec [15] .
The key limitation of this study was the need to use an indirect comparison methodology.
RCTs are correctly the gold standard for comparing treatments, as differences in observed results within a randomized trial may be ascribed to either chance or the randomized 
CONCLUSION
In this indirect analysis of injectable insulin intensification strategies, results with IDegLira were similar or significantly better than those obtained with BB therapy, up-titrated basal insulin therapy, or liraglutide added to basal insulin. Until direct comparisons are available, these indirect results show that IDegLira may offer a useful treatment alternative for patients with type 2 diabetes who have failed to achieve glycemic control using basal insulin therapy. 
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